Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer. Scottish Urological Oncology Group.
A group of 24 patients, all of whom had progressive disease following initial hormone therapy for advanced prostatic carcinoma, were given intravenous methotrexate (30 mg/m2) and doxorubicin (15 mg/m2) at 2-week intervals for a planned 6-treatment course. Seventeen patients completed the full course. Assessment included "quality of life" criteria, using the subjective assessment of performance status, severity of pain and analgesic consumption. Over half of the patients improved in each of these modalities and 8 (33%) improved in all 3. As toxicity was acceptable, low dose chemotherapy may have a part to play in these patients who present a difficult management problem.
Smith
M F
MF
Department of Urology, Law Hospital, Carluke.
Lawson
A H
AH
Kirk
D
D
Kaye
S B
SB
D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010147:Pain Measurement; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life
D000700:Analgesics; D006728:Hormones; D004317:Doxorubicin; D008727:Methotrexate